|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Prazosin#Pharmacology]] |
| {{Prazosin}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==Description==
| |
| | |
| MINIPRESS® (prazosin hydrochloride), a quinazoline derivative, is the first of a new chemical class of antihypertensives. It is the hydrochloride salt of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl) piperazine and its structural formula is:
| |
| {|
| |
| |[[image:prazosin1.png|600px|thumb]]
| |
| |}
| |
| Molecular formula C19H21N5O4•HCl
| |
| | |
| It is a white, crystalline substance, slightly soluble in water and isotonic saline, and has a molecular weight of 419.87. Each 1 mg capsule of MINIPRESS for oral use contains drug equivalent to 1 mg free base.
| |
| | |
| Inert ingredients in the formulations are: hard gelatin capsules (which may contain Blue 1, Red 3, Red 28, Red 40, and other inert ingredients); magnesium stearate; sodium lauryl sulfate; starch; sucrose.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MINIPRESS (PRAZOSIN HYDROCHLORIDE) CAPSULE [PFIZER LABORATORIES DIV PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36c4da56-502e-4da1-acf7-8e81ee453dcc | publisher = | date = | accessdate = 6 March 2014 }}</ref>
| |
| | |
| | |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |